Search

Displaying results 2381 - 2390 of 3483 in total
  1. Drug

    Ensifentrine

    go.drugbank.com/drugs/DB16157
    ApprovedInvestigational

    Ensifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment...

    Synonyms: 2-(9,10-DIMETHOXY-4-OXO-2-(2,4,6-TRIMETHYLPHENYL)IMINO-6,7-DIHYDROPYRIMIDO(6,1-A)ISOQUINOLIN-3-YL)ETHYLUREA, N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  2. Drug

    Lonapegsomatropin

    go.drugbank.com/drugs/DB16220
    ApprovedInvestigational

    Lonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone (somatropin) indicated for the treatment of children 1 year and older, weighing at least 11.5 kg, with growth failure due to ...

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 Inducers
  3. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to t...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  4. Drug

    Miricorilant

    go.drugbank.com/drugs/DB16234
    Investigational

    Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking An...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  5. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with ...

    Synonyms: (s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile, 5-(((1s)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrileCategories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors
  6. Drug

    Seviprotimut-L

    go.drugbank.com/drugs/DB16328
    Investigational

    Seviprotimut-L is under investigation in clinical trial NCT01546571 (Study of a Melanoma Vaccine in Stage Iib, Iic, and III Melanoma Patients).

    Synonyms: Seviprotimut L, Seviprotimut-L
  7. Drug

    Dociparstat sodium

    go.drugbank.com/drugs/DB16481
    Investigational

  8. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    Tisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent, via a protease-cl...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  9. Drug

    CP-96345

    go.drugbank.com/drugs/DB16744
    Experimental

    Categories: Substance P, antagonists & inhibitors
  10. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    It is used to provide functional copies of human adrenoleukodystrophy protein (ALDP) in patients with adrenoleukodystrophy,[L39491] an X-linked genetic disorder characterized by missing or non-functional